Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Ibandronate for Hepatic Osteodystrophy in Liver Cirrhosis
NCT06022237Unknown
- Sponsor
- Institute of Liver and Biliary Sciences
- Start
- Sep 2023
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in hepatic osteodystrophy (HO) comparing Ibandronate with Placebo (2 arms). Primary endpoint: Change in Bone Mineral Density at lumbar spine at 1 year. Status: unknown.
02
Drugs
ibandronate
03
Conditions
hepatic osteodystrophy (HO)
Beyond the preview
Go deeper on NCT06022237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06022237.